Treatment options for multiple sclerosis: Current and emerging therapies

Pharmacotherapy

Volumn 30, Issue 9, 2010, Pages 916-927

  Gawronski, Kristen M ^a   Rainka, Michelle M ^c   Patel, Malti J ^c   Gengo, Francis M ^a,b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c DENT NEUROLOGIC INSTITUTE   (United States)

Author keywords

Adverse effects; Disease modifying agents; Efficacy; Immunomodulators; Monoclonal antibodies; MS; Multiple sclerosis; Oral drugs; Treatment

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE;

ALOPECIA; APHTHOUS ULCER; ARTHRALGIA; ATAXIA; AUTOIMMUNE DISEASE; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHICKENPOX; CHILL; CHOLELITHIASIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GRAFT REJECTION; GRAVES DISEASE; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFLUENZA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LIMB PAIN; LIVER DISEASE; LOWER RESPIRATORY TRACT INFECTION; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MEASLES; MIGRAINE; MOUTH ULCER; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARESTHESIA; PATIENT COMPLIANCE; PHARYNGITIS; PHOTOSENSITIVITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PURPURA; PYOGENIC GRANULOMA; RESPIRATORY TRACT INFECTION; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; RIGOR; SENSORY DYSFUNCTION; SIDE EFFECT; SINUSITIS; SKIN INDURATION; THORAX DISEASE; THORAX PAIN; THROAT IRRITATION; THYROID DISEASE; TRIGEMINUS NEURALGIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 77956160606     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.9.916     Document Type: Review

References (36)

1. National Multiple Sclerosis Society. Just the facts 2007-2008. Available from http://www.national mssociety.org/about-multiple- sclerosis/what-is-ms/ index.aspx. Accessed June 6, 2009.
2. Kim SE. Daclizumab treatment for multiple sclerosis. Pharmacotherapy 2009;29:227-35.
3. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol 2005;58:840-6.
4. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis recent advances and future prospects. Drugs 2008;68:2445-68.
5. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-9.
6. Goodin D. Comparative studies of glatiramer acetate and interferon β. Intl MS J 2008;15:39-41.
7. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology 2008;71:357-64.
8. Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006;12:171-8. (Pubitemid 44134043)
9. U.S. Food and Drug Administration. Tysabri (natalizumab): update of healthcare professional information. Available from http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm199965.htm. Accessed February 15, 2010.
10. Morrissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005;12:74-87.
11. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000;54:1145-55.
12. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64:987-91. (Pubitemid 40388448)
13. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92.
14. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900.
15. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006;13:604-10.
16. Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004;106:270-4. (Pubitemid 38716160)
17. The CAMMS223 Investigators. Alemtuzumab vs interferon β- 1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
18. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66:483-9.
19. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.
20. Brousil JA, Roberts RJ, Schlein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann Pharmacother 2006;40:1814-21.
21. U.S. National Institutes of Health. Cladribine clinical trials. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/ results?term=cladribine&pg=. Accessed June 25, 2009.
22. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323:469-76.
23. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-7.
24. Anonymous. Trial watch: phase III promise for oral multiple sclerosis therapy [news]. Nat Rev Drug Discov 2009;8:98-9.
25. Novartis Pharmaceuticals. Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis (FREEDOMS II). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/show/study/NCT00355134? term= fingolimod&rank=1&show-locs=Y#locn. Accessed June 25, 2009.
26. Weiner HL. Oral laquinimod for treatment of relapsing-remitting multiple sclerosis. Lancet Neurol 2008;7:672-3.
27. Teva Pharmaceuticals. BRAVO study: laquinimod double-blind placebo controlled study in RRMS patients with a rater blinded reference arm of interferon β-1a (Avonex). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/ show/NCT00605215?term=laquinimod&rank=5. Accessed June 25, 2009.
28. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J 2008;15:62-8.
29. U.S. National Institutes of Health. Teriflunomide clinical trials. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/ results?term=teriflunomide. Accessed June 25, 2009.
30. U.S. National Institutes of Health. Dimethyl fumarate clinical trials. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/results?term= dimethyl+fumarate. Accessed June 25, 2009.
31. Osborne R. Buzz around Campath proof-of-concept trial in MS. Nat Biotechnol 2009;27:6-8.
32. Genzyme Corporation and Bayer Healthcare Pharmaceuticals Comparison of alemtuzumab and Rebif efficacy in multiple sclerosis, study II (CARE-MS II). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/show/ NCT00548405?term=alemtuzumab&rank= 47. Accessed June 25, 2009.
33. Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009;66:471-9.
34. U.S. National Institutes of Health. Daclizumab clinical trials. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/ results?term=daclizumab&pg=2. Accessed June 25, 2009.
35. Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis: effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008;117:399-403.
36. Genentech. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://www.clinical trials.gov/ct2/show/study/NCT00087529. Accessed June 14, 2009.